Quantum BioPharma Ltd.
QNTMHealthcare|Biotechnology|CA
$2.10
-0.01 (-0.24%)
DCF Value
$0.09
Tangible Book / Share
$0.27
Cash / Share
$1.46
Next Earnings Report
Mar 26, 2027
EPS est. -$0.75
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.
Upcoming Data Readouts (0)
No upcoming completion dates found in active trials.
Recent Press Releases
Quantum BioPharma Ltd. Announces Filing of Supplement to Management Information Circular Correcting Fractional Share Treatment Under Proposed Share Consolidation and Clarifies MVS Voting Power Threshold
Nov 5, 2026 · GlobeNewsWire
World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
Oct 8, 2026 · GlobeNewsWire
Quantum BioPharma Signs Contract with Thermo Fisher Scientific's Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
Oct 6, 2026 · GlobeNewsWire
IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.
Sep 30, 2026 · GlobeNewsWire
Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO
Sep 24, 2026 · GlobeNewsWire
Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target
Sep 17, 2026 · GlobeNewsWire
Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
Sep 15, 2026 · Newsfile Corp
NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment' in MS Research
Sep 14, 2026 · GlobeNewsWire
Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials
Sep 11, 2026 · GlobeNewsWire
Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment
Sep 9, 2026 · GlobeNewsWire